Other Species / Isoforms
  TACE (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
F26
RPPDDPGFGPHQRLE
0 1
TACE (human) RPPDDPGFGPHQRLE F26
TACE (mouse) RPPEEAGsGsHPRLE S26-p
TACE (rat) RPPEEPGSGSHLRLE S26
P28
PDDPGFGPHQRLEKL
0 1
TACE (human) PDDPGFGPHQRLEKL P28
TACE (mouse) PEEAGsGsHPRLEKL S28-p
TACE (rat) PEEPGSGSHLRLEKL S28
Y82-p
LKRHFKLyLtSStER
0 1
TACE (human) LKRHFKLyLtSStER Y82-p
TACE (mouse) LKRHFKLYLTSSTER Y82
TACE (rat) LKRHFKLYLTSSTER Y82
T84-p
RHFKLyLtSStERFS
0 1
TACE (human) RHFKLyLtSStERFS T84-p
TACE (mouse) RHFKLYLTSSTERFS T84
TACE (rat) RHFKLYLTSSTERFS T84
T87-p
KLyLtSStERFSQNF
0 1
TACE (human) KLyLtSStERFSQNF T87-p
TACE (mouse) KLYLTSSTERFSQNL T87
TACE (rat) KLYLTSSTERFSQNL T87
K102-ub
KVVVVDGkNESEYTV
0 1
TACE (human) KVVVVDGkNESEYTV K102-ub
TACE (mouse) RVVVVDGKEESEYSV K102
TACE (rat) RVVVVDGKEESEYSV K102
N157
EPLWRFVNDTKDKRM
0 1
TACE (human) EPLWRFVNDTKDKRM N157
TACE (mouse) EPLWRFVnDTKDKRM N157-ng
TACE (rat) EPLWRFVNDTKDKRM N157
K168-ub
DKRMLVYkSEDIKNV
0 1
TACE (human) DKRMLVYkSEDIKNV K168-ub
TACE (mouse) DKRMLVYKSEDIKDF K168
TACE (rat) DKRMLVYKSEDIKDF K168
K182-ub
VSRLQSPkVCGYLKV
0 2
TACE (human) VSRLQSPkVCGYLKV K182-ub
TACE (mouse) FSRLQSPKVCGYLNA K182
TACE (rat) FSRLQSPKVCGYLNA K182
K197-ub
DNEELLPkGLVDREP
0 1
TACE (human) DNEELLPkGLVDREP K197-ub
TACE (mouse) DSEELLPKGLIDREP K197
TACE (rat) DSEELLPKGLIDREP K197
N264
RVDDIYRNTSWDNAG
0 1
TACE (human) RVDDIYRNTSWDNAG N264
TACE (mouse) RVDDIYRnTSWDNAG N264-ng
TACE (rat) RVDDIYRNTSWDNAG N264
K302-ub
EKHYNMAkSYPNEEk
0 1
TACE (human) EKHYNMAkSYPNEEk K302-ub
TACE (mouse) ERHFNMAKSFPNEEK K302
TACE (rat) ERHFNMAKSFPNEEK K302
K309-ub
kSYPNEEkDAWDVKM
0 1
TACE (human) kSYPNEEkDAWDVKM K309-ub
TACE (mouse) KSFPNEEKDAWDVKM K309
TACE (rat) KSFPNEEKDAWDVKM K309
K376-ub
YYSPVGKkNIyLNsG
0 1
TACE (human) YYSPVGKkNIyLNsG K376-ub
TACE (mouse) YYNPTVKKNIYLNSG K376
TACE (rat) YYNPGVKKNIYLNSG K376
Y379-p
PVGKkNIyLNsGLTS
Upstream
0 1
Treatment
  • BI2536
TACE (human) PVGKkNIyLNsGLTS Y379-p
TACE (mouse) PTVKKNIYLNSGLTS Y379
TACE (rat) PGVKKNIYLNSGLTS Y379
S382-p
KkNIyLNsGLTSTkN
Upstream
0 1
Treatment
  • BI2536
TACE (human) KkNIyLNsGLTSTkN S382-p
TACE (mouse) KKNIYLNSGLTSTKN S382
TACE (rat) KKNIYLNSGLTSTKN S382
K388-ub
NsGLTSTkNYGkTIL
0 1
TACE (human) NsGLTSTkNYGkTIL K388-ub
TACE (mouse) NSGLTSTKNYGKTIL K388
TACE (rat) NSGLTSTKNYGKTIL K388
K392-ub
TSTkNYGkTILTKEA
0 1
TACE (human) TSTkNYGkTILTKEA K392-ub
TACE (mouse) TSTKNYGKTILTKEA K392
TACE (rat) TSTKNYGKTILTKEA K392
Y433-p
NEDQGGKyVMyPIAV
0 1
TACE (human) NEDQGGKyVMyPIAV Y433-p
TACE (mouse) NEDQGGKYVMYPIAV Y433
TACE (rat) NEDQGGKYVMYPIAV Y433
Y436-p
QGGKyVMyPIAVSGD
0 1
TACE (human) QGGKyVMyPIAVSGD Y436-p
TACE (mouse) QGGKYVMYPIAVSGD Y436
TACE (rat) QGGKYVMYPIAVSGD Y436
K460-ub
CSKQSIYkTIESkAQ
0 1
TACE (human) CSKQSIYkTIESkAQ K460-ub
TACE (mouse) CSKQSIYKTIESKAQ K460
TACE (rat) CSKQSIYKTIESKAQ K460
K465-ub
IYkTIESkAQECFQE
0 1
TACE (human) IYkTIESkAQECFQE K465-ub
TACE (mouse) IYKTIESKAQECFQE K465
TACE (rat) IYKTIESKAQECFQE K465
N539
KKCQEAINATCKGVS
0 1
TACE (human) KKCQEAINATCKGVS N539
TACE (mouse) KKCQEAInATCKGVS N539-ng
TACE (rat) KKCQEAINATCKGVS N539
N551
GVSYCTGNSSECPPP
0 1
TACE (human) GVSYCTGNSSECPPP N551
TACE (mouse) GVSYCTGnSSECPPP N551-ng
TACE (rat) GVSYCTGNSSECPPP N551
D606
SCKVCCRDLSGRCVP
0 1
TACE (human) SCKVCCRDLSGRCVP D606
TACE (mouse) SCKVCCRnLSGPCVP N606-ng
TACE (rat) SCKVCCRNLSGPCVP N606
K620-ub
PYVDAEQkNLFLRKG
0 1
TACE (human) PYVDAEQkNLFLRKG K620-ub
TACE (mouse) PYVDAEQKNLFLRKG K620
TACE (rat) PYVDAEQKNLFLRKG K620
Y702
DKKLDKQYESLsLFH
3 0
TACE (human) DKKLDKQYESLsLFH Y702
TACE (mouse) DKKLDKQyESLSLFH Y702-p
TACE (rat) DKKLDKQyESLSLFH Y702-p
S706-p
DKQYESLsLFHPSNV
0 1
TACE (human) DKQYESLsLFHPSNV S706-p
TACE (mouse) DKQyESLSLFHHSNI S706
TACE (rat) DKQyESLSLFHHSNI S706
K728-ub
SASVRIIkPFPAPQt
Upstream
0 7
Treatment
  • vorinostat
TACE (human) SASVRIIkPFPAPQt K728-ub
TACE (mouse) SASVRIIkPFPAPQt K728-ub
TACE (rat) SASVRIIKPFPAPQt K728
T735-p
kPFPAPQtPGRLQPA
Upstream
Downstream
17 17
Effects on Modified Protein
  • activity, induced
  • enzymatic activity, induced
  • intracellular localization
Effects on Biological Processes:
  • cell cycle regulation
Kinase, in vitro:
  • ERK1 (human)
  • ERK2 (human)
  • P38A (human)
Putative in vivo kinases:
  • ERK1 (human)
  • ERK2 (human)
  • P38A (human)
  • PKCA (human)
  • PKCD (human)
  • PKCE (human)
Treatment
  • anisomycin
  • BX912
  • carbachol
  • EGF
  • GF109203X
  • HSYA
  • IL-1b
  • ischemia
  • LPS
  • LY294002
  • NGF
  • PD184352
  • PD98059
  • phorbol_ester
  • SB203580
  • selumetinib
  • siRNA
  • U0126
  • vemurafenib
  • virus infection
TACE (human) kPFPAPQtPGRLQPA T735-p
TACE (mouse) kPFPAPQtPGRLQAL T735-p
TACE (rat) KPFPAPQtPGRLQAL T735-p
S747-p
QPAPVIPsAPAAPkL
0 1
TACE (human) QPAPVIPsAPAAPkL S747-p
TACE (mouse) QPAAMMPPVPAAPKL P750
TACE (rat) QPAAMMPPVSAAPKL P750
K753-ub
PsAPAAPkLDHQRMD
0 3
TACE (human) PsAPAAPkLDHQRMD K753-ub
TACE (mouse) PPVPAAPKLDHQRMD K756
TACE (rat) PPVSAAPKLDHQRMD K756
T761-p
LDHQRMDtIQEDPst
0 12
TACE (human) LDHQRMDtIQEDPst T761-p
TACE (mouse) LDHQRMDtIQEDPst T764-p
TACE (rat) LDHQRMDTIQEDPst T764
S767-p
DtIQEDPstDsHMDE
0 6
TACE (human) DtIQEDPstDsHMDE S767-p
TACE (mouse) DtIQEDPstDsHADD S770-p
TACE (rat) DTIQEDPstDsHVDD S770-p
T768-p
tIQEDPstDsHMDED
0 6
TACE (human) tIQEDPstDsHMDED T768-p
TACE (mouse) tIQEDPstDsHADDD T771-p
TACE (rat) TIQEDPstDsHVDDD T771-p
S770-p
QEDPstDsHMDEDGF
0 8
TACE (human) QEDPstDsHMDEDGF S770-p
TACE (mouse) QEDPstDsHADDDGF S773-p
TACE (rat) QEDPstDsHVDDDGF S773-p
K779-ub
MDEDGFEkDPFPNsS
0 1
TACE (human) MDEDGFEkDPFPNsS K779-ub
TACE (mouse) ADDDGFEKDPFPNsS K782
TACE (rat) VDDDGFEKDPFPNSS K782
S785-p
EkDPFPNsSTAAksF
Upstream
0 4
Treatment
  • selumetinib
  • vemurafenib
TACE (human) EkDPFPNsSTAAksF S785-p
TACE (mouse) EKDPFPNsSTAAKsF S788-p
TACE (rat) EKDPFPNSSAAAKsF S788
K790-ub
PNsSTAAksFEDLtD
0 3
TACE (human) PNsSTAAksFEDLtD K790-ub
TACE (mouse) PNsSTAAKsFEDLTD K793
TACE (rat) PNSSAAAKsFEDLTD K793
S791-p
NsSTAAksFEDLtDH
Upstream
4 54
Treatment
  • FGF1
  • ischemia
  • serum
  • U0126
TACE (human) NsSTAAksFEDLtDH S791-p
TACE (mouse) NsSTAAKsFEDLTDH S794-p
TACE (rat) NSSAAAKsFEDLTDH S794-p
T796-p
AksFEDLtDHPVTRS
0 1
TACE (human) AksFEDLtDHPVTRS T796-p
TACE (mouse) AKsFEDLTDHPVTRS T799
TACE (rat) AKsFEDLTDHPVTRS T799
K805-ub
HPVTRSEkAAsFkLQ
0 1
TACE (human) HPVTRSEkAAsFkLQ K805-ub
TACE (mouse) HPVTRSEKAAsFKLQ K808
TACE (rat) HPVTRSEKAAsFKLQ K808
S808-p
TRSEkAAsFkLQRQN
2 3
TACE (human) TRSEkAAsFkLQRQN S808-p
TACE (mouse) TRSEKAAsFKLQRQS S811-p
TACE (rat) TRSEKAAsFKLQRQS S811-p
K810-ub
SEkAAsFkLQRQNRV
0 1
TACE (human) SEkAAsFkLQRQNRV K810-ub
TACE (mouse) SEKAAsFKLQRQSRV K813
TACE (rat) SEKAAsFKLQRQSRV K813
S819-p
QRQNRVDsKETEC__
Upstream
Downstream
3 8
Effects on Modified Protein
  • enzymatic activity, induced
Treatment
  • FGF1
  • selumetinib
  • serum
  • U0126
  • vemurafenib
TACE (human) QRQNRVDsKETEC__ S819-p
TACE (mouse) QRQSRVDsKETEC__ S822-p
TACE (rat) QRQSRVDSKETEC__ S822